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The potential role of infectious agents and
pelvic inflammatory disease in ovarian
carcinogenesis
Kasper Ingerslev1* , Estrid Hogdall2, Tine Henrichsen Schnack3, Wojciech Skovrider-Ruminski4, Claus Hogdall3
and Jan Blaakaer1
Abstract
Background: The etiological cause of ovarian cancer is poorly understood. It has been theorized that bacterial or
viral infection as well as pelvic inflammatory disease could play a role in ovarian carcinogenesis.
Aim: To review the literature on studies examining the association between ovarian cancer and bacterial or viral
infection or pelvic inflammatory disease.
Methods: Database search through MEDLINE, applying the medical subject headings: “Ovarian neoplasms”, AND
“Chlamydia infections”, “Neisseria gonorrhoeae”, “Mycoplasma genitalium”, “Papillomaviridae”, or “pelvic inflammatory
disease”. Corresponding searches were performed in EMBASE, and Web of Science. The literature search identified
935 articles of which 40 were eligible for inclusion in this review.
Results: Seven studies examined the association between bacterial infection and ovarian cancer. A single study
found a significant association between chlamydial infection and ovarian cancer, while another study identified
Mycoplasma genitalium in a large proportion of ovarian cancer cases. The remaining studies found no association.
Human papillomavirus detection rates varied from 0 to 67% and were generally higher in the Asian studies than in
studies from Western countries. Cytomegalovirus was the only other virus to be detected and was found in 50%
of cases in a case-control study. The association between ovarian cancer and pelvic inflammatory disease was
examined in seven epidemiological studies, two of which, reported a statistically significant association.
Conclusions: Data indicate a potential association between pelvic inflammatory disease and ovarian cancer. An
association between ovarian cancer and high-risk human papillomavirus genotypes may exist in Asia, whereas an
association in Western countries seems unlikely due to the low reported prevalence. Potential carcinogenic bacteria
were found, but results were inconsistent, and further research is warranted.
Keywords: Ovarian cancer, Bacterial infection, Viral infection, Pelvic inflammatory disease, Carcinogenesis
Background
Ovarian cancer (OC) is a major threat to female health,
with a global prevalence of 239,000 cases in 2012 [1]. Due
to the lack of symptoms in early stage OC, advanced
disease is often present at the time of diagnosis [2].
Almost 90% of OC originates from epithelial cells,
which have been thought to arise from the surface
mesothelial lining of the ovaries. However, recent
research has indicated that a proportion of serous
epithelial OC could originate in precancerous lesions
called “serous tubal intraepithelial carcinomas” (STICs)
located in the fimbriated end of the fallopian tubes [3].
This is an important finding because previous theories
of ovarian carcinogenesis have been unable to explain
the fact that precancerous lesions have never been
identified in the ovaries [3].
The female internal genitalia and the peritoneal cavity
are accessible to outside pathogens through the genital
tract. The mesothelial lining of the peritoneal cavity is
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identical in both sexes. However, primary serous peri-
toneal cancer, which may represent a continuum with
serous OC [3], occurs almost exclusively in female pa-
tients [4]. This suggests that extrinsic factors could play
a crucial role in ovarian carcinogenesis. Furthermore,
epidemiological studies have demonstrated that patients
with tubal factor infertility have a higher risk of OC [5].
Since the fallopian tubes are often affected by pelvic in-
flammatory disease (PID), it is therefore highly rele-
vant to consider the potential role of infectious
agents in OC. Previous reviews have focused on hu-
man papillomavirus (HPV) and OC, but this review is
the first to include studies on all bacterial and viral
infections as well as studies on pelvic inflammatory
disease (PID).
Material and methods
To review the existing literature on OC and infectious
agents, we performed a systematic literature search by
means of a database search for English language articles
published in the period from 1980 to 2016. Using the
Pubmed research tool, the keyword: “ovarian neoplasms”
was by means of the Boolean logical “AND”, combined
with the following keywords: “Chlamydia infections”
(MeSH), “Neisseria gonorrhoeae” (MeSH), “Mycoplasma
genitalium” (MeSH), “Papillomaviridae” (MeSH), “pelvic
inflammatory disease” (MeSH). Correspondent searches
were performed in EMBASE and Web of Science. The ini-
tial search identified 935 articles. After removal of 130
duplicates, 805 studies remained for further analysis. Con-
tents were outside the scope of the present review in
740 articles that were excluded. The remaining 65
articles were subjected to full-text screening. Ori-
ginal studies, examining the association between in-
fectious agents and ovarian cancer by use of tissue-
based or serologic methods were included. Epidemio-
logical studies examining the association between
pelvic inflammatory disease and ovarian cancer were
also included. Case-reports and reviews were ex-
cluded, leaving a total of 40 articles to be included
in the review. More detailed information on the
search strategy is given in the “Additional file 1” to
this article.
Viral agents investigated in relation to ovarian
carcinogenesis
Table 1 summarises the viruses investigated in relation
to OC, and their potential oncogenic mechanisms.
Table 1 Carcinogenic mechanisms of investigated viruses in relation to ovarian cancer
Virus Viral family Key viral transforming
factors
Mechanisms Associated cancers
Human papillomavirus Papillomaviridae E6
E7
Inhibition of apoptosis
Immune evasion
Cell cycle arrest
Immune evasion [8, 10, 11]
Anal/rectal cancer
Cervical cancer
Oro-pharyngeal cancer
(Ovarian cancer)a
Penile cancer
Vaginal
Vulvar cancer
Epstein bar virus Herpesviridae EBNA 1
EBNA 2
EBNA-3A
Latent membrane
protein 1
Inhibition of apoptosis
B-cell growth transformation
Cell cycle disruption
Cell cycle disruption
Inhibition of apoptosis
Promotion of cell immortalisation [48, 49]
Burkitt lymphoma
Gastric adenocarcinoma
Hodgkin lymphoma
Nasopharyngeal carcinoma
Non-Hodgkin lymphoma
(Ovarian cancer)
Post-transplant lymphoproliferative
disease
Cytomegalovirus Herpesviridae IE1/IE2 Inhibition of antiviral immune response
Inhibition of apoptosis
Mucoepidermoid carcinoma of
salivary glands
(Ovarian cancer)
US28 gene Enhanced proliferative signaling [44, 45]
John Cunningham virus/
BK virus
Polyomaviridae T-antigen/t-antigen Cell cycle disruption Inhibition of
apoptosis [56]
(Ovarian cancer)
Hepatitis C virus Flaviviridae (Indirect) Chronic inflammation and oxidative stress
Inhibition of antioxidant systems
Hepatocellular carcinoma
(Ovarian cancer)
(Direct)
NS5B
NOS2A
NS3/4A protease
Cell cycle disruption
Inhibition of apoptosis
Inhibition of DDR response [51–53]
DDR Double-stranded DNA Repair, EBNA Epstein Barr virus nuclear antigen, IE Immediate early genes, NOS2A Nitric oxide synthase 2A, NS3/4A/5B Nonstructural
protein 3/4A/5B
aCausality is controversial and is still under investigation
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Human papillomavirus infection
HPV infection is a prerequisite for cervical cancer
development and is implicated in a range of other
cancer forms such as vulvar, penile, anal, and oropha-
ryngeal cancers. To date, The International Agency for
Research on Cancer has classified 12 HPV subtypes as
human carcinogens: HPV16/18/31/33/35/39/45/51/52/
56/58/59 [6]. In HPV-induced tumorigenesis, the viral
oncogenes E6 and E7 are integrated into the host cell
DNA, allowing viral oncoproteins to be expressed by
the cell [7]. The carcinogenic mechanisms of these
oncoproteins involve the ability of E6 to form a
trimeric complex with P53 and the cellular E3 ubiqui-
tin ligase, E6AP. This complex induces proteasomal
degradation of P53, which leads to inhibition of cell-
regulatory mechanisms and apoptosis and, therefore,
permits continuous cell proliferation despite irrepar-
able DNA damage [8]. E7 can cause degradation of
retinoblastoma protein, which is an important regula-
tor of the cell cycle [9]. Furthermore, E7 can interact
with several cell cycle regulators including cyclins,
cyclin-dependent kinases, CDKs-inhibitors, cullin 2,
histone deacetylase, AP-1, E2F1, and E2F6 [10]. These
actions enable the virus to resume the replication-
competent state within the infected cells, which is
essential for viral DNA synthesis. E6 and E7 can also
exhibit immunomodulatory effects by downregulating
expression of various inflammatory cytokines and by
reducing the production of antiviral interferons [11].
HPV is the most studied infectious agent in relation to
OC, and the available studies are summarised below.
Six case-control studies, with 11–50 cases of OC, were
identified that examined the relation between HPV and
OC [12–17]. The applied methods of analysis were
either tissue-based methods or serologic assays and
included in-situ hybridisation, immunohistochemistry,
enzyme-linked immunosorbent serologic assay (ELISA),
southern blot hybridisation technique, and polymerase
chain reaction (PCR)-based technologies. Only one study
found a statistically significant association between HPV
and OC [12]. This study was the largest and included 50
cases with OC and a control group with 30 patients with
non- malignant ovarian lesions. In-situ hybridisation and
immunohistochemistry were used to detect the HPV 16
E6 gene in the tumour specimens. The highest detection
rates were obtained by in-situ hybridisation, with a
prevalence of 52% among cases as compared to 6.7%
among controls (OR: 16.7 95% CI: 3.2–71.4). The
remaining smaller studies, found no or non-significant
associations [13–17].
Twenty-two case-series and cross-sectional studies
reporting on the prevalence of HPV in OC tissue were
identified (Table 2). HPV 16 was most frequently found
and was reported in eight studies, giving a combined
total of 60 cases. Ten studies did not find HPV in any of
the samples [18–27]. The remaining studies reported a
HPV prevalence ranging between 0.5 and 66.7% [28–39].
Interestingly, the reported HPV prevalence varied ac-
cording to the geographical region. Among the 572 cases
of OC in Europe and USA combined, 18 cases (3.1%)
were positive for HPV DNA. Studies from the Middle
East and Asia, with 347 combined cases of OC, reported
123 cases to be HPV DNA positive (35.4%).
Recently, sequencing data from The Cancer Genome
Atlas (TCGA) database have been utilised to detect HPV
oncogene expression in ovarian tumours. Using such
data, Roos et al. concluded that six samples in 405
(1.5%) were positive for HPV18 oncogene expression
[40]. However, Khoury et al. performed a similar analysis
on 419 serous cystadenocarcinomas from the TCGA
database and did not find signs of HPV infection [41].
Moreover, other studies present data that support poten-
tial HPV 18 contamination of the TCGA sequencing
database and, consequently, question the validity of posi-
tive findings [42, 43].
Cytomegalovirus infection
Cytomegalovirus (CMV) is under increasing focus as a
carcinogenic virus. It is speculated that rather than initi-
ating malignant transformation, CMV can enhance the
growth and migration of tumour cells through a process
called “oncomodulation” [44]. For instance, the forma-
tion of metastasis may be aided by the capacity of CMV
to adhere to and disrupt the endothelial cell integrity by
activating β1α5 integrin on the surface of tumour cells
[45]. However, data also indicate that CMV has inherent
antiapoptotic and cell cycle modulatory effects [45]. A
single study has examined the relation between OC and
CMV. The study detected CMV infection in 12 (50%)
out of 24 cases with OC and in three (50%) out of six
cases of borderline ovarian tumours. No signs of CMV
infection were found in the control group consisting of
normal ovarian tissue [13]. These findings have not been
confirmed by others.
Epstein-Barr virus and hepatitis C virus infection
Epstein-Barr virus (EBV) is present in more than 90% of
the global adult population and causes latent infection in
the host. [46] It exhibits tropism for epithelial cells,
lymphocytes, and mesenchymal cells and is associated
with a range of human cancers, including nasopharyn-
geal carcinoma (NPC) and lymphomas [47]. Its carcino-
genic mechanisms include the actions of latent antigens
that display effects similar to those of high-risk HPV
oncogenes E6 and E7. An example is EBV nuclear anti-
gen (EBNA)-1 that can induce proteasomal degradation
of P53 and corresponding inhibition of apoptosis [48].
Likewise, EBNA-3A and -3C play an important role in
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cell cycle regulation and EBNA-2 antigen is suspected
to cause primary B-cell growth transformation and
maintain human B-cell immortalisation [49]. Hepatitis
C virus (HCV) is another investigated microorganism
in relation to OC. Chronic HCV infection greatly in-
creases the risk of subsequent hepatocellular carcin-
oma [50]. The mechanisms are not fully understood
but may entail different pathways. The chronic inflam-
mation enhances a pro-carcinogenic microenviron-
ment through the release of nitric oxide (NO) and
reactive oxygen species (ROS). This process is further
mediated by the ability of HCV to increase the cellular
generation of NO and ROS [51] and by its capacity to
weaken the antioxidant defence of the host. [52] A
more direct pathway involves the ability of HCV to
impair phosphorylation of the ataxia telangiectasia
mutated (ATM) kinase substrate, histone 2A.X, which
plays a role in initiating cellular response to double-
stranded DNA breaks [53]. Despite the obvious car-
cinogenic potential of EBV and HCV, only a single
study has investigated their potential role in relation
to OC. However, this study did not detect EBV or
HCV in 419 serous cystadenocarcinomas from the
TCGA database [41].
Polymyoma virus infection
Finally, a single study has analysed tissue samples for
the presence of the BK virus and John Cunningham
virus [18]. The oncogenic potential of polymyoma
viruses has largely been attributed to viral proteins T-
antigen and t-antigen through their interactions with
various cellular proteins, including tumour suppressor
proteins p53 and pRb [54, 55]. Furthermore, the
capability of John Cunningham virus T- antigen to
transform rodent cells has previously been demon-
strated [56]. In the included study, however, poly-
myoma viruses were not detected in any of the
ovarian cancer tissue samples, nor in the benign
controls.
Bacterial agents investigated in relation to
ovarian carcinogenesis
In relation to OC, previous research has focused on the
potential association between Chlamydia trachomatis
(C. trachomatis), Mycoplasma genitalium (M. genitalium),
and Neisseria gonorrhoeae (N. gonorrhoeae) [13, 18, 57–61].
An overview of the potential carcinogenic mechanisms of
these bacteria is provided in Table 3.
Table 2 Studies reporting on HPV prevalence in ovarian cancer tissue
Author & publication year Detection method HPV genotypes
found
Number of cases
of EOC
Number of HPV
positive cases
HPV prevalence (%)
Ingerslev et al. (2016) [28] PCR 18 191 1 0.5
Al-Shabanah et al. (2013) [29] PCR 16,18,45 100 42 42.0
Malisic et al. (2012) [30] PCR 16 54 4 7.4
Bilyk et al. (2011) [31] PCR 16,18 53 9 16.9
Idahl et al. (2010) [18] PCR 52 0 0
Giordano et al. (2008) [32] PCR Not specified 50 1 2.0
Wentzensen et al. (2008) [19] PCR 74 0 0
Atalay et al. (2007) [33] PCR 16,33 94 8 8.5
Quirk et al. (2006) [20] PCR 16 0 0
Yang et al. (2003) [34] PCR 16,18 56 19 33.9
Ip et al. (2002) [35] PCR 16,18 60 6 10
Li et al. (2002) [36] PCR Not specified 39 26 66.6
Antilla et al. (1999) [21] PCR 98 0 0
Chen et al. (1999) [22] PCR 20 0 0
Strickler et al. (1998) [37] ELISA 16 16 1 6.2
Zimna et al. (1997) [38] PCR 18 18 7 38.8
Anwar et al. (1996) [23] PCR 3 0 0
Runnebaum et al. (1995) [24] PCR 26 0 0
Trottier et al. (1995) [25] PCR 22 0 0
Lai et al. (1994) [39] PCR 16,18 18 11 61.1
Beckmann et al. (1991) [26] PCR 18 0 0
de Villiers (1986) [27] Southern blot hybridisation 7 0 0
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Chlamydia trachomatis infection
C. trachomatis is a small, obligate intracellular bacter-
ium that has developed several mechanisms to im-
prove its own survival and replication within the host.
It can upregulate the production of reactive oxygen
species (ROS) through the Mitochondrial Nod-like
Family Member NLRX1 [62]. ROS production is nor-
mally a cellular defence mechanism against invading
microorganisms. However, C. trachomatis can subvert
cellular defences and use ROS to improve its own
growth through activation of caspase-1 [62]. The
resulting increased levels of ROS can lead to double-
stranded DNA breaks in the infected cell. Further-
more, C. trachomatis can impair the DNA damage
response (DDR) through inhibition of DDR proteins
pATM and 53BP1 [63]. Despite the DNA damage, the
chlamydia-infected cells continue to proliferate due to
increased MAPK signalling and cyclin E expression
[63]. Finally, C. trachomatis can initiate proteasomal
degradation of P53 through interaction with the phos-
phorylated ubiquitin ligase Murine Double Minute 2,
leading to inhibition of apoptosis [64]. Combined,
these mechanisms promote bacterial survival, but they
can also potentially lead to genomic instability, dis-
ruption of the cell cycle, and inhibition of apoptosis,
all of which are among the hallmarks of cancer [65].
Therefore, C. trachomatis is a suitable candidate for
ovarian carcinogenesis. However, the literature on the
subject is scarce, and an association between C. tra-
chomatis and OC has been found in only two studies.
One case-control study was based on fresh ovarian
tissues from 39 women undergoing laparotomy [13].
The tissue samples, which included 24 cases of OC,
six borderline tumours, and nine normal ovaries, were
tested for the presence of C. trachomatis DNA by
PCR techniques. C. trachomatis DNA was detected in
87.5% of the malignant tumours and 50% of the bor-
derline ovarian tumours as compared to none of the
benign ovarian tissue samples (OR = 32 (95% CI: 3.33,
307.65).
A study by Ness et al. included 117 women with
OC and 171 healthy controls [60]. Serologic testing
for IgG antibodies of the extracellular elementary
bodies (EB) of C. trachomatis was performed. Patients
with EOC were more likely to have high levels of C.
trachomatis EB than the controls in adjusted analysis.
In a subgroup analysis, the probability of having OC
was insignificantly increased in patients with the high-
est levels of IgG EB antibodies compared to the
group with the lowest levels (OR = 1.9 95% CI 0.9–
3.9). However, these findings are controversial, since
four other serologic studies with a total of 626 cases of
OC found no association [57–59, 61]. Likewise, a single
tissue- based study that included 51 OC cases did not find
an association [18].
Neisseria gonorrhoeae & Mycoplasma genitalium
infection
N. gonorrhoeae is a small, gram-negative diplococcus
that infects epithelial cells and causes cervicitis/urethritis
and PID. It has been associated with prostate and blad-
der cancer [66, 67]. One study has reported that N.
gonorrhoeae can cause DNA strand breaks, affect the cell
cycle progression, and can decrease the levels of P53
within infected cells [68].
M. genitalium is under increasing focus for its role in
PID. Like N. gonorrhoeae, its propensity for malignant
transformation of host cells is unclear. However, one
study revealed that persistent infection of benign human
prostate cells with M. genitalium resulted in increased
migration/invasion [69]. Furthermore, it induced the
acquisition of anchorage-independent growth, which
allows cells to detach from the surrounding extracellular
matrix and metastasise. Finally, it induced karyotypic
entropy and malignant transformation proven by the
formation of xenograft tumours in immune-compromised
mice [69].
Very few studies have investigated the association
between M. genitalium or N. gonorrhoeae and OC.
Only one study reported an association, M. genitalium
DNA being detected in 16 (59.3%) out of 27 samples
by a combined PCR and ELISA technique. [70] How-
ever, in two separate studies, Idahl et al. found no
Table 3 Carcinogenic mechanisms of investigated bacteria in relation to ovarian cancer
Microorganism Suspected mechanisms Potentially associated cancers
Chlamydia trachomatis Inhibition of apoptosis
Production of reactive oxygen species
Inhibition of DDR [62, 64]
Cervical squamous cell carcinoma
Ovarian cancer
Neisseria Gonorrhoeae DNA strand breaks. Inhibition of P53.
Cell cycle disruption [68]
Bladder cancer
Prostate cancer
Ovarian cancer
Mycoplasma Genitalium Acquisition of anchorage-independent growth
Inhibition of apoptosis. Karyotypic entropy [69]
Ovarian cancer
Prostate cancer
DDR Double-stranded DNA Repair
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association between M. genitalium or N. gonorrhoeae
and OC [18, 57].
Pelvic inflammatory disease
Microorganisms that cannot directly induce cellular
transformation may still play a role in OC oncogenesis
due to the paradoxical effect of the host inflammatory
response. It has long been recognised that the cells
involved in innate and adaptive immune responses are
recruited to the site of tumorigenesis. Here, they can
release a multitude of tumour promoting inflammatory
cytokines, chemokines, and ROS that can potentially
facilitate tumour cell migration, metastasis, and angio-
genesis [65]. Cancer has aptly been described as “a
wound that does not heal [71]”. Several conditions asso-
ciated with pelvic inflammation such as perineal talc use
and endometriosis have been demonstrated to increase
the risk of OC [72]. Likewise, ovulation is speculated to
induce focal damage and inflammation on the ovarian
surface epithelium, and factors that reduce the number
of lifetime ovulatory cycles have been shown to reduce
the risk of OC [73]. Consequently, it has been speculated
that PID could play a role in ovarian carcinogenesis, and
the potential association between PID and OC have been
investigated in seven case-control studies (Table 4). The
majority of studies relied on patient-reported outcomes
and identified cases of PID through interviews or question-
naires. Risch et al. reported a statistically significant associ-
ation between PID and OC (odds ratio (OR) 1.53; 95% CI
1.10–2.13) [74]. Moreover, they found a dose-response ef-
fect in relation to repeated episodes of PID, implying a
higher risk of OC with increasing episodes of PID (OR
1.88; 95% CI 1.13–3.12). A prospective, population-
based study from Taiwan verified the diagnosis of PID
by the International Statistical Classification of Dis-
eases and Related Health Problems codes registered
in a national database [75]. After 3 years of follow-
up, a higher risk of OC was observed in the case
group (hazard ratio (HR) 1.92; 95% CI 1.27–2.92)). In
this study, the association was also stronger when
analysis was restricted to cases exposed to more
episodes of PID (HR 2.46; 95% CI 1.48–4.09) [75].
However, a statistically significant association between
PID and OC could not be confirmed in any of the
remaining studies [72, 74, 76–79].
Discussion
The reviewed studies were very heterogeneous in terms
of study population, study design, and the analysis
methods used.
However, based on the reviewed studies, it is fair to
conclude that high-risk HPV is unlikely to be associated
with OC in Western countries. Interestingly, a higher
prevalence was consistently reported in Asia and the
Middle East. This finding is supported by previous re-
views focusing on HPV and ovarian cancer [80, 81] and
a potential association may exist in these regions. The
geographic variation could be caused by varying potency
of HPV strains. Thus, it has been demonstrated that
latent infection of the cervix uteri with the non- European
variant of HPV 16 is associated with a 2- to 9-fold higher
risk of cancer or high- grade cancer precursors, compared
to infection with the European variant [82]. Differing gen-
etic predispositions between ethnical groups may also be a
factor because polymorphisms of the TP 53 gene or the
promoter of the tumour necrosis factor alpha gene have
been associated with increased vulnerability to HPV onco-
genes [83, 84]. Lastly, environmental or life-style factors
could play a role. For instance, the global incidence of
EBV infection among adults is estimated to be over 90%,
and there is strong evidence linking EBV infection to the
development of NPC [47]. Despite the ubiquity of infec-
tion, the incidence of NPC is very low in most regions.
However, dramatically elevated rates are observed in cer-
tain parts of Asia, and dietary factors, such as the intake
of salt-preserved fish, are thought to play a role [85]. This
Table 4 Case-control studies on the association between PID and ovarian cancer
Author & publication year Region Data collection Number of cases Number of controls Odds/Hazard- ratios (HR)
Rasmussen et al. (2013) [78] Denmark Interview 554 1.564 0.83 95% CI: 0.65–1.05
Lin et al. (2011) [75] Taiwan Database 67.936 135.872 1.92 95% CI: 1.27–2.92 (HR)
2.46 95% CI: 1.48–4.09c (HR)
Merritt et al. (2007) [76] Australia Questionnaire 1.576 1.509 1.15 95% CI: 0.85–1.57
Ness et al. (2000) [72] USA Interview 616 1.367 1.3 95% CI: 0.6–2.5
Parazzini et al. (1996) [79] Italy Questionnaire/interview 971 2.758 0.7 95% CI: 0.4–1.3
Risch et al. (1995) [74] Canada Interview 450 564 1.53 95% CI: 1.10–2.13a
1.88 95% CI: 1.13–3.12b
Shu et al. (1989) [77] Hong Kong Interview 172 172 3.0 95% CI: 0.3–30.2
aOne episode of PID
bTwo or more episodes of PID
cFive or more episodes of PID
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underlines that, even though infection with oncogenic vi-
ruses is common, cancer is a rare event that can arise
from a combination of genetic, environmental, and life-
style factors.
Most of the epidemiological studies found an associ-
ation between OC and PID, but only two studies re-
ported a statistically significant association [74, 75]. It is
noteworthy, however, that these studies also identified a
dose- response effect. This is one of the key points in
Hill’s criteria for causation that state that a biological
gradient must be present, with more exposure to the
suspected agent leading to a larger effect [86]. These
findings are supported by studies that found evaluated
markers of inflammation such as CRP and interleukins
to be significantly associated with an increased risk of
OC [87]. A possible limitation to the reviewed studies is
that they relied primarily on patient-reported outcomes,
which may be subject to recall bias. Furthermore, due to
the potential subclinical course of PID, patients can be un-
aware of previous episodes. This is supported by studies
that have demonstrated a relatively high seroprevalence of
chlamydia antibody titres in women that reported no his-
tory of PID, and this issue would tend to produce bias to-
wards the null [88, 89].
Interestingly, CMV was reported in 50% of cases in a sin-
gle study, but this finding requires confirmation in future
and larger studies. No other viral agent was detected.
The only detected bacteria were C. trachomatis and M.
genitalium. The results of this review do not support an
association between C. trachomatis and OC, the majority
of studies reporting negative results. The association be-
tween M. genitalium and OC was investigated and found
in only a single study and more research is needed.
Several factors may account for the conflicting results.
First of all, there may be no connection between the
investigated infectious agents and OC. Secondly, the
heterogeneity of analysis methods, study populations, and
study designs may play a part. However, other explanations
must be discussed. Importantly, it is unclear to what extent
signs of microbiological agents are present in a tumour that
arises decades after infection. For some oncogenic viruses,
like high-risk HPV, expression of viral oncogenes is obligate
for the maintenance of the malignant phenotype [90]. In
these cases, viral genes will remain integrated and detect-
able in tumour cell DNA. But another potential mechanism
is debated in the “hit and run” hypothesis. Here, integration
of viral transforming genes and potential epigenetic repro-
gramming of host cells initiate tumorigenesis, but the viral
gene expression is subsequently lost during neoplastic de-
velopment [91]. Accordingly, it has been demonstrated
that CMV oncogenes IE1 and IE2 can cooperate with
adenovirus E1A gene to transform rat kidney cells. How-
ever, expression of the transforming oncogenes was absent
in the clonal cell lines from the transformed foci [92].
Finally, other oncogenic agents act more indirectly by
inducing chronic inflammation that may function as an
initiator or promoter of carcinogenesis [93]. Consequently,
the involved pathogen may no longer be present when
cancer is diagnosed. For instance, despite the established
role of HCV in hepatocellular carcinoma, only a minority
of transformed hepatocytes contain viral RNA [94].
These examples highlight the fact that the abscense
of microbiological agents in tumour tissue does not
rule out their potential role in the transformation of
host cells. These issues seem to strengthen the need
for serologic studies. However, serologic methods are
limited by the fact that antibody levels are likely to de-
cline over time. In a study from Finland, 43% of
women had declining C. trachomatis antibody titres
6 years after the diagnosis of PID [95]. Moreover, not all
patients with prior chlamydial infection will have detect-
able antibodies [96].
These obstacles call for a revised strategy in the
attempt to uncover the potential role of infectious
agents in OC. It is fair to assume that signs of micro-
biological presence will be easier to detect when the
interval between primary infection and investigation is
short. Therefore, it seems more relevant to investigate
precursor lesions for the presence of potential micro-
biological agents [91]. Until recently, this has been
impossible due to the lack of a clearly defined prema-
lignant lesion to OC. However, this has changed be-
cause increasing evidence indicates that STIC lesions
in the distal fallopian tubes are precursor lesions to
serous epithelial OC, which constitutes the majority
of OC cases [3]. Yet, no explanation has been formu-
lated as to why STIC lesions arise. Since the fallopian
tubes are often affected and damaged by chronic PID,
it is biological plausible that pathogens with trans-
forming capacities, or the chronic inflammation they
induce, could lead to subsequent neoplastic trans-
formation. We therefore recommend that future stud-
ies focus on the detection of bacterial or viral agents in
fallopian tube tissue samples with STIC lesions verified
through the “Sectioning and Extensively Examining of the
Fimbriated end” protocol.
Conclusion
The reviewed articles indicate a potential association
between PID and OC. An association between OC and
high-risk HPV genotypes may exist in Asia, whereas an
association in Western countries seems unlikely due to
the low reported prevalence. Two studies reported an
association between bacterial agents and OC, but the
majority of bacterial studies reported negative findings.
However, the available literature was scarce and more
studies are warranted.
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